Beyer, KatharinaStraten, VeraRemmers, SebastiaanMacLennan, StevenGandaglia, GiorgioWillemse, Peter-Paul M.Herrera, RonaldOmar, Muhammad ImranRussell, BethHuber, JohannesKreuz, MarkusAsiimwe, AlexAbbott, TomBriganti, AlbertoVanhemelrijck, MiekeRoobol, Monique JMacLennan, SaraThe PRIAS ConsortiumThe ERSPC Rotterdam Study GroupThe PIONEER Consortium2022-07-122022-07-122022-05-05Beyer, K, Straten, V, Remmers, S, MacLennan, S, Gandaglia, G, Willemse, P-P M, Herrera, R, Omar, M I, Russell, B, Huber, J, Kreuz, M, Asiimwe, A, Abbott, T, Briganti, A, Vanhemelrijck, M, Roobol, M J, MacLennan, S, The PRIAS Consortium, The ERSPC Rotterdam Study Group & The PIONEER Consortium 2022, 'Secondary Treatment for Men with Localized Prostate Cancer : a pooled analysis of PRIAS and ERSPC-Rotterdam data within the PIONEER data platform', Journal of Personalized Medicine, vol. 12, no. 5, 751. https://doi.org/10.3390/jpm120507512075-4426ORCID: /0000-0003-1405-6964/work/115777583ORCID: /0000-0002-2691-8421/work/115777737ORCID: /0000-0002-1597-3126/work/115777767https://hdl.handle.net/2164/18835Funding PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. The views communicated within are those of PIONEER. Neither the IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.8425765engSDG 3 - Good Health and Well-beingprostate canceractive surveillancetreatment choicepatient decision-makingoncologytreatment selectionRC0254 Neoplasms. Tumors. Oncology (including Cancer)Other777492Supplementary DataRC0254Journal article10.3390/jpm12050751125